A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

Brief description of study

This study is about testing two different treatments for a type of lung cancer called EGFR-mutant lung cancer. The first treatment is a medicine called osimertinib, which patients will take by mouth every day. They'll take it for three rounds, and then the doctors will check their blood to see if the medicine is working. If the medicine is not working, some patients will get another treatment called chemotherapy along with osimertinib, while others will keep taking osimertinib alone. The doctors will monitor how well the treatments are working by taking pictures of the inside of the body and checking the blood again if the cancer starts to grow again.


Clinical Study Identifier: s22-00369
ClinicalTrials.gov Identifier: NCT04410796
Principal Investigator: Joshua K Sabari.
Other Investigators: Samantha VanMaanen, Jason E Sandler, Jennifer Wu, Jessica Wang, Cristian C Papazoglu Statescu, Andrea Popescu-Martinez, Salman Rafi Punekar, Sally Lau, David Mendoza, Natalia Cherkassky, Vamsidhar Velcheti, Melissa L Martinez, Theresa Ryan, Kirby Rodriguez, Elaine Shum, Mary Lynn R Nierodzik.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.